Mount Sinai finds meta-cognitive therapy more effective for adult ADHD patients
Mary Solanto, Ph.D., Associate Professor in the Department of Psychiatry and Director of the Attention Deficit/Hyperactivity Disorder Center at The Mount Sinai Medical Center examined the effectiveness of a 12-week meta-cognitive therapy group. The intervention was intended to enhance time management, organizational, and planning skills/abilities in adults with ADHD.
“We observed adults with ADHD who were assigned randomly to receive either meta-cognitive therapy or a support group,” said Dr. Solanto. “This is the first time we have demonstrated efficacy of a non-medication treatment for adult ADHD in a study that compared the active treatment against a control group that was equivalent in therapist time, attention, and support.”
The study observed 88 adults with rigorously diagnosed ADHD, who were selected following structured diagnostic interviews and standardized questionnaires. Participants were randomly assigned to receive meta-cognitive therapy or supportive psychotherapy in a group setting. Groups were equated for ADHD medication use.
Participants were evaluated by an independent (blind) clinician using a standardized interview assessment of core inattentive symptoms and a subset of symptoms related to time-management and organization. After 12 weeks, the MCT group members were significantly more improved than those in the support group. The MCT group was also more improved on self-ratings and observer ratings of these symptoms.
Meta-cognitive therapy uses cognitive-behavioral principles and methods to teach skills and strategies in time management, organization, and planning. Also targeted were depressed and anxious thoughts and ideas that undermine effective self-management. The supportive therapy group matched the MCT group with respect to the nonspecific aspects of treatment, such as providing support for the participants, while avoiding discussion of time management, organization, and planning strategies.
In addition to Dr. Solanto, the research team included David Marks, Ph.D., Assistant Professor of Psychiatry, and Jeanette Wasserstein, Ph.D., Assistant Clinical Professor of Psychiatry at Mount Sinai School of Medicine.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses The Mount Sinai Hospital and Mount Sinai School of Medicine. The Mount Sinai Hospital is one of the nation's oldest, largest and most-respected voluntary hospitals. Founded in 1852, Mount Sinai today is a 1,171-bed tertiary-care teaching facility that is internationally acclaimed for excellence in clinical care. Last year, nearly 60,000 people were treated at Mount Sinai as inpatients, and there were nearly 450,000 outpatient visits to the Medical Center.
Mount Sinai School of Medicine is internationally recognized as a leader in groundbreaking clinical and basic science research, as well as having an innovative approach to medical education. With a faculty of more than 3,400 in 38 clinical and basic science departments and centers, Mount Sinai ranks among the top 20 medical schools in receipt of National Institute of Health (NIH) grants.
Media Contact
More Information:
http://www.mountsinai.orgAll latest news from the category: Studies and Analyses
innovations-report maintains a wealth of in-depth studies and analyses from a variety of subject areas including business and finance, medicine and pharmacology, ecology and the environment, energy, communications and media, transportation, work, family and leisure.
Newest articles
How marine worms regenerate lost body parts
The return of cells to a stem cell-like state as the key to regeneration. Many living organisms are able to regenerate damaged or lost tissue, but why some are particularly…
Nano-scale molecular detective
New on-chip device uses exotic light rays in 2D material to detect molecules. Researchers have developed a highly sensitive detector for identifying molecules via their infrared vibrational “fingerprint”. Published in Nature…
Novel CAR T-cell therapy
… demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors. The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors….